MedPath

Detectie van tumorweefsel met behulp van Bevacizumab-IRDye800CW in combinatie met een optisch beeldvormingssysteem bij patiënten die de HIPEC procedure ondergaan, een haalbaarheidsstudie.

Recruiting
Conditions
VEGF-­Targeted Near-­Infrared Fluorescence imaging in Peritoneal Carcinomatosis
Registration Number
NL-OMON27201
Lead Sponsor
niversity Medical Center Groningen
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Recruiting
Sex
Not specified
Target Recruitment
10
Inclusion Criteria

Age ≥ 18 years.

-Patients with histopathological proven peritoneal carcinomatosis from colorectal origin who are
scheduled to undergo the HIPEC procedure

Exclusion Criteria

- Concomitant malignancies, except for adequately treated basocellular carcinoma of the skin or in situ carcinoma of the cervix uteri. Subjects with prior malignancies must be disease-­free for at least 5 years.

- Distance metastasis (liver / lungs)

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Visualization of fluorescent tumor tissue confirmed by ex vivo immunohistochemistry or fluorescence microscopy of excised specimen.
Secondary Outcome Measures
NameTimeMethod
Improvement of the detection rate of tumor tissue using Multispectral Fluorescence Reflectance Imaging (MFRI) by calculation the Peritoneal Carcinomatosis Index (PCI).
© Copyright 2025. All Rights Reserved by MedPath